The British Columbia Pharmacare newsletter was published on February 27, 2017
As noted in the newsletter, for the pricing period starting April 1, 2017, the maximum price that suppliers can charge for generic LCA drugs will continue as:
- 20% of the equivalent brand product’s list price for oral solids
- 35% of the equivalent brand product’s list price for drugs available in other forms
- 18% or 15% of the equivalent brand product’s list price for drugs subject to Pan-Canadian pricing.
The edition of the newsletter also provided information on changes to generic pricing processes. According to this update, effective April 1, 2017, there will no longer be an annual confirmation of generic drug pricing. The current annual pricing period (April 1 to March 31) will be replaced with an indefinite pricing period, except for competitive MALP (maximum accepted list price) generic drug listings.
Please visit the BC Health & Drug Coverage website for further information.
To receive updates similar to this one please be sure to sign up for Market Access Signals, our free e-mail newsletter service.